DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Lotus Eye Hospital and Institute Limited — Board Meeting Intimation

NSE 1 hr ago·2 Nov 2026, 7:04 am

Lotus Eye Hospital and Institute

Lotus Eye Hospital and Institute Limited has announced a board meeting scheduled for November 11, 2026. The primary agenda for this meeting is to consider and approve the company's unaudited financial results for the first half of the fiscal year 2026-27, which covers the period ending September 2026.

This update is significant for investors as it provides an early glimpse into the hospital's operational performance and financial health during the first half of the year. The unaudited results will offer insights into revenue trends, profitability, and overall business momentum, helping shareholders assess the company's current trajectory.

Investors should watch for the release of these results to gauge the hospital's growth prospects and operational efficiency. The data will be crucial for evaluating the company's performance against market expectations and competitors in the healthcare sector.